Tumor infiltrating lymphocytes (TIL) were cultured with “moxibustion serum”(MS), and the results were examined by flow cytometry. The results indicated that MS could enhance the proliferation of TIL,accelerate it to...Tumor infiltrating lymphocytes (TIL) were cultured with “moxibustion serum”(MS), and the results were examined by flow cytometry. The results indicated that MS could enhance the proliferation of TIL,accelerate it to reach the exponential growth phase, and assist recombinant interleukin 2 (rIL-2) to enhance successively the percentage of CD3^+ positive cells, maintain the number of CD4^+ positive T cells, promote greatly the percentage of CD8^+ positive T cells among TILs, and reverse the CD4^+/CD8^+ ratio. Such cooperative effects rely on relative specificity of acupoints. It is suggested that MS is beneficial to the growth of TIL both in the aspects of proliferation and phenotypes.展开更多
目的弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是一组具有明显异质性的大细胞淋巴瘤,通过多种检查手段早期识别DLBCL预后较差的亚群,对于预后判断和治疗选择具有重要作用。本研究选择了几种相对少见免疫表型表达的DLBCL...目的弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是一组具有明显异质性的大细胞淋巴瘤,通过多种检查手段早期识别DLBCL预后较差的亚群,对于预后判断和治疗选择具有重要作用。本研究选择了几种相对少见免疫表型表达的DLBCL类型(C-myc/Bcl-2共表达、NF-κB/p65阳性、CD5阳性及CD30阳性的DLBCL)和EB病毒(epstein-barr virus,EBV)阳性的DLBCL病例进行研究,通过检测肿瘤微环境细胞中程序性死亡受体-1(programmed death receptor-1,PD-1)表达情况,探讨PD-1表达相关的影响因素及其表达对相应DLBCL发生和发展的影响。方法收集贵州医科大学附属医院2010-01-01-2018-08-31诊断的120例DLBCL患者资料,通过普通免疫组化染色(C-myc、Bcl-2、NF-κB/p65和CD30)、免疫组化双标(CD5、PAX5)及EBER原位杂交检测筛选出上述特殊类型的病例并分组,普通免疫组化染色检测肿瘤微环境中PD-1蛋白表达情况。收集临床病理资料并随访,对实验数据进行统计学分析。结果120例DLBCL患者中,PD-1肿瘤浸润淋巴细胞(tumor infiltraling lymphoeytes,TILs)阳性病例共有63例(52.5%,63/120);其中C-myc/Bcl-2共表达组中PD-1(+)-TILs病例27例(69.25%,27/39),NF-κB/p65阳性组30例(68.2%,30/44),CD30阳性组17例(73.9%,17/23),CD5阳性组14例(77.8%,14/18),EBV阳性组中为5例(55.6%,5/9)。PD-1(+)-TILs与PD-1(-)-TILs组病例之间IPI评分(χ^2=4.514,P=0.034)和Ann Arbor分期(χ^2=4.760,P=0.029)差异有统计学意义,PD-1(+)-TILs组分期晚、IPI指数高;PD-1-TILs表达在阳性组C-myc/Bcl-2共表达(χ^2=6.485,P=0.011)、NF-κB/p65(χ^2=6.851,P=0.009)、CD30(χ^2=5.232,P=0.022)、CD5(χ^2=5.426,P=0.040)表达率明显高于阴性组,差异有统计学意义;PD-1-TILs表达在EBV阳性组与阴性组之间差异无统计学意义,χ^2=0.001,P=0.970。生存分析98例随访病例中,PD-1(+)-TILs组病例的总生存率(overall survival,OS)明显低于PD-1(-)-TILs组患者,χ^2=14.652,P<0.001;在C-myc/Bcl-2共表达(χ^2=4.071,P=0.049)、NF-κB/p65的核表达(χ^2=4.833,P=0.025)及CD30阳性DLBCL(χ^2=5.207,P=0.024)中PD-1(+)-TILs组的生存状况也明显较PD-1(-)-TILs组病例差;多因素回归分析显示,PD-1(+)-TILs是DLBCL的独立危险因素,HR=38.170,P=0.036。结论PD-1表达在C-myc/Bcl-2共表达阳性、NF-κB/p65阳性、CD30阳性和CD5阳性的DLBCL中明显增高,在EBV阳性的DLBCL中增加不明显,PD-1在肿瘤微环境细胞中的表达可能是(C-myc/Bcl-2共表达阳性、NF-κB/p65阳性和CD30阳性)DLBCL不良预后评估的相关因素。展开更多
文摘Tumor infiltrating lymphocytes (TIL) were cultured with “moxibustion serum”(MS), and the results were examined by flow cytometry. The results indicated that MS could enhance the proliferation of TIL,accelerate it to reach the exponential growth phase, and assist recombinant interleukin 2 (rIL-2) to enhance successively the percentage of CD3^+ positive cells, maintain the number of CD4^+ positive T cells, promote greatly the percentage of CD8^+ positive T cells among TILs, and reverse the CD4^+/CD8^+ ratio. Such cooperative effects rely on relative specificity of acupoints. It is suggested that MS is beneficial to the growth of TIL both in the aspects of proliferation and phenotypes.
文摘目的弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是一组具有明显异质性的大细胞淋巴瘤,通过多种检查手段早期识别DLBCL预后较差的亚群,对于预后判断和治疗选择具有重要作用。本研究选择了几种相对少见免疫表型表达的DLBCL类型(C-myc/Bcl-2共表达、NF-κB/p65阳性、CD5阳性及CD30阳性的DLBCL)和EB病毒(epstein-barr virus,EBV)阳性的DLBCL病例进行研究,通过检测肿瘤微环境细胞中程序性死亡受体-1(programmed death receptor-1,PD-1)表达情况,探讨PD-1表达相关的影响因素及其表达对相应DLBCL发生和发展的影响。方法收集贵州医科大学附属医院2010-01-01-2018-08-31诊断的120例DLBCL患者资料,通过普通免疫组化染色(C-myc、Bcl-2、NF-κB/p65和CD30)、免疫组化双标(CD5、PAX5)及EBER原位杂交检测筛选出上述特殊类型的病例并分组,普通免疫组化染色检测肿瘤微环境中PD-1蛋白表达情况。收集临床病理资料并随访,对实验数据进行统计学分析。结果120例DLBCL患者中,PD-1肿瘤浸润淋巴细胞(tumor infiltraling lymphoeytes,TILs)阳性病例共有63例(52.5%,63/120);其中C-myc/Bcl-2共表达组中PD-1(+)-TILs病例27例(69.25%,27/39),NF-κB/p65阳性组30例(68.2%,30/44),CD30阳性组17例(73.9%,17/23),CD5阳性组14例(77.8%,14/18),EBV阳性组中为5例(55.6%,5/9)。PD-1(+)-TILs与PD-1(-)-TILs组病例之间IPI评分(χ^2=4.514,P=0.034)和Ann Arbor分期(χ^2=4.760,P=0.029)差异有统计学意义,PD-1(+)-TILs组分期晚、IPI指数高;PD-1-TILs表达在阳性组C-myc/Bcl-2共表达(χ^2=6.485,P=0.011)、NF-κB/p65(χ^2=6.851,P=0.009)、CD30(χ^2=5.232,P=0.022)、CD5(χ^2=5.426,P=0.040)表达率明显高于阴性组,差异有统计学意义;PD-1-TILs表达在EBV阳性组与阴性组之间差异无统计学意义,χ^2=0.001,P=0.970。生存分析98例随访病例中,PD-1(+)-TILs组病例的总生存率(overall survival,OS)明显低于PD-1(-)-TILs组患者,χ^2=14.652,P<0.001;在C-myc/Bcl-2共表达(χ^2=4.071,P=0.049)、NF-κB/p65的核表达(χ^2=4.833,P=0.025)及CD30阳性DLBCL(χ^2=5.207,P=0.024)中PD-1(+)-TILs组的生存状况也明显较PD-1(-)-TILs组病例差;多因素回归分析显示,PD-1(+)-TILs是DLBCL的独立危险因素,HR=38.170,P=0.036。结论PD-1表达在C-myc/Bcl-2共表达阳性、NF-κB/p65阳性、CD30阳性和CD5阳性的DLBCL中明显增高,在EBV阳性的DLBCL中增加不明显,PD-1在肿瘤微环境细胞中的表达可能是(C-myc/Bcl-2共表达阳性、NF-κB/p65阳性和CD30阳性)DLBCL不良预后评估的相关因素。
